Cargando…

Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials

BACKGROUND: Health utilities are preference-based measures for health states which are typically used in economic analyses to estimate quality-adjusted life years. Our aim is to report the standard SF-6D health utility scores in Japanese patients with hepatitis C virus (HCV) during treatment with di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Younossi, Zobair, Stepanova, Maria, Omata, Masao, Mizokami, Masashi, Walters, Mercedes, Hunt, Sharon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282717/ https://www.ncbi.nlm.nih.gov/pubmed/28143559 http://dx.doi.org/10.1186/s12955-017-0598-8

Ejemplares similares

Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir
por: Younossi, Zobair M., et al.
Publicado: (2016)

Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens
por: Younossi, Zobair M., et al.
Publicado: (2016)

Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States
por: Jayasekera, Channa R., et al.
Publicado: (2017)

Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir
por: Younossi, Zobair M., et al.
Publicado: (2016)

Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease
por: Sayiner, Mehmet, et al.
Publicado: (2016)

The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV)
por: Golabi, Pegah, et al.
Publicado: (2016)

Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity
por: Younossi, Zobair M., et al.
Publicado: (2017)

Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C)
por: Birerdinc, Aybike, et al.
Publicado: (2012)

Development and validation of a primary sclerosing cholangitis-specific health-related quality of life instrument: CLDQ-PSC
por: Younossi, Zobair M., et al.
Publicado: (2023)

Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C
por: Ogawa, Eiichi, et al.
Publicado: (2020)

Impact of healthcare reform on the payer mix among young adult emergency department utilizers across the United States (2005–2015)
por: Bush, Haley, et al.
Publicado: (2018)

Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B
por: Buti, Maria, et al.
Publicado: (2021)

Sofosbuvir‐based regimens for the treatment of chronic hepatitis C in severe renal dysfunction
por: Cox‐North, Paula, et al.
Publicado: (2017)

Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen
por: Agarwal, Sanjay Kumar, et al.
Publicado: (2017)

The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin
por: Younossi, Zobair M, et al.
Publicado: (2012)

Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor
por: Stepanova, Maria, et al.
Publicado: (2016)

Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa
por: Boyer, Sylvie, et al.
Publicado: (2022)

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure
por: Mir, Fazia, et al.
Publicado: (2017)

Treatment Outcomes for Patients Undergoing Hemodialysis with Chronic Hepatitis C on the Sofosbuvir and Daclatasvir Regimen
por: Butt, Nazish, et al.
Publicado: (2019)

Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain
por: Esteban, Rafael, et al.
Publicado: (2022)

Sofosbuvir–velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals
por: Izumi, Namiki, et al.
Publicado: (2018)

Implementation of baby boomer hepatitis C screening and linking to care in gastroenterology practices: a multi-center pilot study
por: Younossi, Zobair M., et al.
Publicado: (2016)

Knowledge-Based Identification of Soluble Biomarkers: Hepatic Fibrosis in NAFLD as an Example
por: Page, Sandra, et al.
Publicado: (2013)

Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2018)

Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States
por: Golabi, Pegah, et al.
Publicado: (2016)

Clinical outcomes and resource utilisation in Medicare patients with chronic liver disease: a historical cohort study
por: Younossi, Zobair M, et al.
Publicado: (2014)

Non-Invasive markers for hepatic fibrosis
por: Baranova, Ancha, et al.
Publicado: (2011)

Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens
por: Chen, Jianhong, et al.
Publicado: (2017)

Sofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care Setting
por: Gayam, Vijay, et al.
Publicado: (2018)

Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis
por: Stepanova, Maria, et al.
Publicado: (2015)

Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C
Publicado: (2019)

Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand
por: Sirinawasatien, Apichet, et al.
Publicado: (2020)

Sofosbuvir and Velpatasvir Regimen Outcome for Chronic Hepatitis C Patients With End-Stage Renal Disease Undergoing Hemodialysis
por: Shahid, Salman, et al.
Publicado: (2023)

Patients With Diabetes and Chronic Liver Disease Are at Increased Risk for Overall Mortality: A Population Study From the United States
por: Stepanova, Maria, et al.
Publicado: (2017)

Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients
por: Shin, Hyun Phil, et al.
Publicado: (2017)

Outcomes after sofosbuvir-containing regimens for hepatitis C virus in patients with decompensated cirrhosis: a real-world study
por: Ji, Fanpu, et al.
Publicado: (2017)

Efficacy and Safety of Sofosbuvir-based Regimens in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta-analysis
por: Zhang, Wenyan, et al.
Publicado: (2023)

Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis
por: Sayiner, Mehmet, et al.
Publicado: (2017)

The Efficacy and Safety of Sofosbuvir-Containing Regimen in the Treatment of HCV Infection in Patients with Haemoglobinopathy
por: Hussein, N.R.
Publicado: (2017)

Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study
por: Ruane, Peter, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ehglsd9rl60oh07vn8surkcc6p